Cough/Cold Combination Final Monograph Includes Four-Ingredient Combos
This article was originally published in The Tan Sheet
Executive Summary
FDA has designated combinations of analgesic-antipyretic, expectorant and nasal decongestant ingredients, as well as analgesic-antipyretic, antitussive, expectorant and nasal decongestant combinations, as Category I in the final monograph on cough/cold combinations
You may also be interested in...
Antitussive Combo With Wick Delivery Needs Two Clinical Studies – FDA
Two clinical studies are needed to support cough/cold monograph status for a menthol/camphor/eucalyptus oil combination product with a wick delivery system, FDA stated at a recent "feedback" meeting on Lil' Drug Store's antitussive Vaporizer in a Bottle
Antitussive Combo With Wick Delivery Needs Two Clinical Studies – FDA
Two clinical studies are needed to support cough/cold monograph status for a menthol/camphor/eucalyptus oil combination product with a wick delivery system, FDA stated at a recent "feedback" meeting on Lil' Drug Store's antitussive Vaporizer in a Bottle
Antitussive Combo With Wick Delivery Needs Two Clinical Studies – FDA
Two clinical studies are needed to support cough/cold monograph status for a menthol/camphor/eucalyptus oil combination product with a wick delivery system, FDA stated at a recent "feedback" meeting on Lil' Drug Store's antitussive Vaporizer in a Bottle